Remove Events Remove Leads Remove Physicians Remove Safety
article thumbnail

Revolutionizing Pharmacovigilance with Proactive Signal Detection

PM360

Up to now, drug safety teams have relied primarily on reactive reporting systems for pharmacovigilance (PV) or real-world drug safety monitoring. Most traditional signal detection methods focus on disproportionality, meanwhile calling attention to higher-than-expected correlations between the suspect drug and an adverse event (AE).

Safety 106
article thumbnail

ESMO 2022: Ten key takeaways on Europe’s top oncology event

Clarivate

As part of the Drugs to Watch program, Clarivate experts use proprietary data sources, landscape and event monitoring and deep market knowledge to identify key drug developments expected to have a significant impact on patients and markets. 8] Median PFS (secondary endpoint) also significantly improved with fruquintinib versus control (3.7

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Using data analytics to better manage care transitions

Clarify Health

Poor care transition management can lead to fragmented healthcare delivery, often leading to increased patient readmissions, compromised health outcomes, and elevated costs. By actively managing transitions, hospitals can reduce the likelihood of adverse events, improve patient safety, and enhance overall healthcare quality.

article thumbnail

AbbVie’s Skyrizi® shows long-term efficacy in psoriatic arthritis

European Pharmaceutical Review

The long-term data analyses of the Phase III KEEPsAKE 1 and 2 trials also revealed no new observed safety signals through 100 weeks. ” Skyrizi was generally well-tolerated and no new safety signals were noted in both KEEPsAKE 1 and 2 at 100 weeks of treatment. . Serious treatment-emergent adverse events (TEAEs) occurred at 7.6

Safety 66
article thumbnail

X4 Pharmaceuticals announces positive top-line results for WHIM Syndrome drug

pharmaphorum

X4 Pharmaceuticals has announced positive top-line results from a Phase 3 study of its lead investigational therapy, mavorixafor, in people with warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome. Dubbed 4WHIM, the trial was initially designed to enrol 18-28 patients.

article thumbnail

ReCor Medical Announces Two Concurrent JAMA Network Publications of Study Results on the Paradise Ultrasound Renal Denervation System for the Treatment of Hypertension

Legacy MEDSearch

In addition, pooled analysis results from the combined primary efficacy endpoint and safety data from RADIANCE SOLO, RADIANCE TRIO, and RADIANCE II were concurrently published in JAMA Cardiology. The study also achieved its primary safety composite outcome with no major adverse events observed. mmHg (p<0.0001).

article thumbnail

15th Annual Pre-Filled Syringes and Injectable Drug Devices Conference

pharmaphorum

This event will not only bring you key insights you need to expand and enhance your injectable device portfolio but will also give you the opportunity to network with key players throughout the industry. Blaine Martin, Digital Health, New Product Planning and Portfolio Expansion, Franchise Lead, Fertility, Merck.